A multi-part, double blind study to assess safety, tolerability and efficacy of tropifexor (LJN452) in PBC patients

Registry ID

EUCTR2015-001590-41

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE2

Sponsor

Novartis Pharma Services AG

Start date

2015-12-15

Completion date

2018-08-02

Last update

2026-08-16

Conditions

• primary biliary cholangitis

Summary

• To determine the safety and tolerability of daily dosing of LJN452 in patients with Primary Biliary Cholangitis • To determine the effect of LJN452 on cholestatic markers in patients with Primary Biliary Cholangitis. More specifically, in Part 2 to determine the dose-response relationship of LJN452 on GGT following 12 weeks of treatment

Locations

• , , Germany
• , , Poland

View on source registry